In this study, using an in vitro tube formation model, we observed that SZ117, a monoclonal antibody against matrix metalloproteinase-2 (MMP2), attenuated a capillary-like tube structure formed by tumor endothelial cell 3B11 and human sarcoma cell MG63. In addition, gelatin zymography showed that SZ117 markedly inhibited MMP2 activity, but did not affect the capability of MMP9-mediated gelatin degradation. These data suggest that SZ117 might have an anti-tumor angiogenic effect and that angiogenic tumor cells and MMP2 may be targeted by monoclonal antibodies for novel anti-tumor angiogenic and anti-cancerous drug discovery.
Get full access to this article
View all access options for this article.
References
1.
RibattiD. The discovery of antiangiogenic molecules: a historical review. Curr Pharm Des, 2009; 15:345–352.
2.
CarmelietP, JainRK. Molecular mechanisms and clinical applications of angiogenesis. Nature, 2011; 473:298–307.
PrestaLG, ChenH, O'ConnorSJ, ChisholmV, MengY.G, KrummenL, WinklerM, FerraraN. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res, 1997; 57:4593–4599.
LogesS, MazzoneM, HohensinnerP, CarmelietP. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell, 2009; 15:167–170.
7.
EbosJM, LeeCR, Cruz-MunozW, BjarnasonGA, ChristensenJG, KerbelRS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell, 2009; 15:232–239.
KuceraT, LammertE. Ancestral vascular tube formation and its adoption by tumors. Biol Chem, 2009; 390:985–994.
11.
ZhouQ, WilliamB. K, JinL, PaulS. Tumor endothelial cell tube formation model for determining anti-angiogenic activity of tRNA synthetase cytokine. Methods, 2008; 44:190–194.
12.
ZhouQ, KapoorM, GuoM, Belani1R, XuX, KiossesWB, HananM, ParkC, ArmourE, DoM-H, NangleLA, PaulS, YangX-L. Orthogon of a human tRNA synthetase active site to achieve multifunctionality. Nat Struct Mol Biol, 2010; 17:57–61.
13.
HuX, ShenF, DongN, LiP, RuanC. Preparation and study of monoclonal antibody to matrix metalloproteinase-2. Chin J Path, 2005; 5:876–881.
14.
ZhouQ, ZhaoY, LiP, RuanC. A monoclonal antibody (SZ-53) against thrombomodulin inhibits thrombin-mediated release of t-PA and PGI2 from endothelial cells. Nouv Rev Fr Hematol, 1991; 33:329–342.
15.
ZhaoY, DongN, ShenF, XieL, HeY, LiuF, RuanC. Two novel monoclonal antibodies to VWFA3 inhibit VWF-collagen and VWF-platelet interactions. J Thromb Haemost, 2007; 5:1963–1970.
16.
ZhouQ, ZhaoJ, WildmerT, SimsPJ. Normal hemostasis but defective hematopoietic response to growth factors in mice deficient in phospholipid scramblase 1. Blood, 2002; 99:4030–4038.
17.
ZhouQ, Ben-EfraimI, BigcasJL, JunqueiraD, WiedmerT, SimsPJ. Phospholipid scramblase 1 binds to the promoter region of the inositol 1,4,5-triphosphate receptor type 1 gene to enhance its expression. J Biol Chem, 2005; 280:35062–35068.
18.
ZhangLZ, MeiJ, QianZK, CaiXS, JiangY, HuangWD. The role of VE-cadherin in osteosarcoma cells. Pathol Oncol Res, 2009; 16:111–117.
